A5056903024- Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Vascular Tumors and Angiosarcomas
- Tumors and Oncological Cases
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cardiac tumors and thrombi
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Multiple and Secondary Primary Cancers
- Oral and Maxillofacial Pathology
- Angiogenesis and VEGF in Cancer
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Cell Adhesion Molecules Research
- Effects of Radiation Exposure
- Telomeres, Telomerase, and Senescence
- Cancer-related molecular mechanisms research
- RNA Interference and Gene Delivery
- Nonmelanoma Skin Cancer Studies
- Medical Imaging and Pathology Studies
Shanghai Medical College of Fudan University
2010-2025
Hubei University of Medicine
2014-2025
Taihe Hospital
2014-2025
Fudan University Shanghai Cancer Center
2016-2025
Fudan University
2011-2023
Christie's
2015
Creative Commons
2015
Fundación Juan March
2015
Zhongnan Hospital of Wuhan University
2006-2009
Wuhan University
2005-2009
Background/Aims: LncRNAs have been reported to be vital regulators of the progression osteosarcoma, although underlying mechanisms are not completely understood. Methods: The levels MALAT1 and miR-129-5p expression were measured using qRT-PCR. Cell growth was determined CCK-8 colony formation assays. migration invasion detected wound healing Transwell assays, respectively. Tumor with a xenograft model. Results: significantly up-regulated in osteosarcoma tissues compared adjacent non-tumor...
We aimed to evaluate the value of [68 Ga]Ga-DOTA-FAPI-04 PET/CT for diagnosis recurrent soft tissue sarcoma (STS), compared with [18F]FDG PET/CT.A total 45 patients (21 females and 24 males; median age, 46 years; range, 18-71 years) 13 subtypes STS underwent examination within 1 week assessment local relapse or distant metastasis. Positive lesions on images were verified by biopsy 3-month follow-up. Wilcoxon matched-pairs signed-rank test was used compare semiquantitative values (SUVmax TBR)...
Abstract Background HL-085 is a selective, orally administered MEK1/2 inhibitor. We aimed to evaluate the safety and efficacy of in patients with advanced melanoma harboring NRAS mutations. Methods This was multicenter phase 1 study. twice daily standard 3 + dose-escalation design (10 dose cohorts; 0.5–18 mg daily), followed by expansion at recommended II (RP2D). The primary endpoints included tolerability, dose-limiting toxicity (DLT), maximum tolerated (MTD) RP2D. Results Between September...
Abstract Purpose: This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as first-line treatment for patients advanced or metastatic soft-tissue sarcoma (STS). Patients Methods: received PLD (30 mg/m2; day 1) in combination IFO (1.8 g/m2; days 1–5) every 21 until disease progression, unacceptable toxicities, patient death, up six cycles. The primary endpoint was progression-free...
Abstract Background Our previous studies demonstrated that 1-Pyrroline-5-carboxylate (P5C) released by prostate cancer cells inhibits T cell proliferation and function increasing SHP1 expression. We designed this study to further explore the influence of P5C on metabolism, produced an antibody for targeting restore functions cells. Method co-immunoprecipated from analyzed proteins were bound it using liquid chromatography mass spectrometry (LC/MS-MS). The metabolism was also detected...
Dermatofibrosarcoma protuberans (DFSP) is a rare, plaque-like tumor of the cutaneous tissue occurring more on trunk than extremities and neck. More 95% DFSP present anomalies 17q22 22q13 chromosomal regions leading to fusion COL1A1 PDGFB genes. Surgery optimal treatment for DFSP, but less effective in locally advanced or metastatic patients, as case with chemotherapy radiotherapy. The aim this study was assess retrospectively therapeutic activity safety imatinib 22 Chinese patients...
Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy characterized by poor prognosis, with median survival time of approximately 3 to 4 months. In this report, we present case involving 59-year-old patient diagnosed ATC, who experienced swift local recurrence pulmonary metastasis following radical thyroidectomy. Comprehensive Sanger sequencing the resected tumor tissue revealed no mutations in TERT promoter or BRAF V600E gene. The exhibited rapid post-surgery was...
Metastasis is considered to be the major cause of mortality in patients with cancer, and gastric cancer a highly metastatic cancer. In present study, anti-metastatic activity chitooligosaccharide (COS) human cells its underlying mechanism were investigated. It was found that COS significantly inhibited SGC-7901 cell proliferation metastasis dose-dependent manner, as observed by MTT, wound-healing Transwell assays. Quantitative real-time polymerase chain reaction western blot analysis...
Current pemetrexed/platinum chemotherapy does not produce a satisfactory therapeutic response in advanced lung cancer patients. The aim of this study was to determine whether the administration gefitinib, tyrosine kinase inhibitor (TKI), intercalated with could improve efficacy chemotherapy-naïve patients non-squamous NSCLC without subsequent gefitinib maintenance therapy. Treatment-naïve stage IIIB or IV were randomly assigned receive pemetrexed (500 mg/m2 d1) and either cisplatin (75...
Bone metastasis of cancer can be a result from systemic blood spreading or vertebral venous plexus spreading. Systemic pathway induced bone happen in any the body since is considered to random. However, it remains unknown whether there pattern related metastasis. In this study, we explored patterns patients whose primary tumors had been well identified.
Abstract Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block binding of PD-1 with its ligands PD-L1 PD-L2. Methods In this phase 2 trial, patients locally advanced or metastatic melanoma who had failed conventional treatment (chemotherapy, targeted therapy, interferon, IL-2, et al.) were recruited. The administrated 3 mg/kg every weeks until disease progression,...
Hypoxia-inducible factor-1α (HIF-1α), a critical transcription factor to reduced O2 availability, has been demonstrated be extensively involved in tumor survival, aggressive progression, drug resistance and angiogenesis. Thus it considered as potential anticancer target. Triptolide is the main principle responsible for biological activities of Traditional Chinese Medicine tripterygium wilfordii Hook F. possesses great chemotherapy cancer with its broad-spectrum anticancer, antiangiogenesis,...
Abstract Chondroitin polymerizing factor (CHPF) is an important member of glycosyltransferases involved in the biosynthesis chondroitin sulfate (CS). However, relationship between CHPF and malignant melanoma (MM) still unknown. In this study, it was demonstrated that up-regulated MM tissues compared with adjacent normal skin its high expression correlated more advanced T stage. Further investigations indicated over-expression/knockdown could promote/inhibit proliferation, colony formation...
11505 Background: Anti-PD-1 antibody had showed encouraging activity as salvage treatment in patients with certain subtypes of advanced soft tissue sarcoma. However, its role first-line setting is uncertain. We assessed the safety and sintilimab, an anti-PD-1 antibody, combined doxorubicin (ADM) ifosfamide (IFO) undifferentiated pleomorphic sarcoma (UPS), synovial (SS), myxoid liposarcoma (MLPS) de-differentiated (DDLPS). Methods: This a single-arm, phase 2 study. Systemic naïve metastatic...
This study aimed to evaluate the effect of anti-PD-1 combined with temozolomide as front-line therapy in patients unresectable advanced melanoma.The records melanoma first treated pembrolizumab plus temozolomide, alone, or temozolomide-based chemotherapy at three cancer centers from May 2018 February 2020 were reviewed. Patients followed up until death October 30, 2020. Data retrospectively reviewed and statistically analyzed for best objective response rate (ORR) progression-free survival...
Previous studies on cancer of unknown primary (CUP) mainly focus treatment and prognosis in western populations lacked clinical evaluation different IHC markers, so this study aimed to evaluate characteristics CUP recommend a diagnostic strategy from single center China.Data 625 patients with were retrospectively collected reviewed. The ranged age 20 91 years, female-to-male ratio 1.3:1. predominant histological type was poor or undifferentiated adenocarcinomas (308; 49.3%). results...